Skip to content

EPS (Basic) at other companies

Baxter International logo
Baxter InternationalBAX
-$0.03-112%
PTH
Pelthos Therapeutics Inc.PTHS
-$3.09+3.7%
Rigel Pharmaceuticals logo
Rigel PharmaceuticalsRIGL
$0.47-26.6%
BridgeBio Pharma logo
BridgeBio PharmaBBIO
-$0.84+4.5%
RFL
Rafael Holdings, Inc.RFL
-$0.08+57.9%
Opko Health logo
Opko HealthOPK
-$0.07+30.0%

Other financials

Income statement

See full
Revenue$9.1M-22.0%
Gross profit$7.2M-30.0%
Operating income-$3.1M-342%
Net income-$3.3M-362%
EPS (diluted)-$0.22-375%

Balance sheet

See full
Cash & equivalents$11.0M-27.1%
Total debt$4.8M-7.1%
Total equity$21.6M-24.5%
Total assets$71.0M+1.5%

Cash flow

See full
Operating cash flow$387.0K-90.1%
CapEx--100%
Free cash flow$387.0K-89.9%

Valuation

See full
Market cap$97.09M+142%
Enterprise value$90.91M+212%
P/S2.3×+1.4×

Profitability

See full
Gross margin82.9%-1.4pp
Operating margin-17.2%-125pp
Net margin-17.6%-103pp
FCF margin3.3%

Returns & leverage

See full
Return on equity-29.4%-86.3pp
Debt / equity0.2×0.0×
Current ratio-0.3×

Where this comes from

Reported directly by Cumberland Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:EarningsPerShareBasic.

The official record: Cumberland Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about Cumberland Pharmaceuticals's eps (basic).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Cumberland Pharmaceuticals's EPS (basic)?
Cumberland Pharmaceuticals (CPIX) reported EPS (basic) of -$0.22 in Q1 2026.
How has Cumberland Pharmaceuticals's EPS (basic) changed year-over-year?
Cumberland Pharmaceuticals's EPS (basic) decreased by 375.0% year-over-year, from $0.08 to -$0.22.
What is the long-term trend for Cumberland Pharmaceuticals's EPS (basic)?
Over 4 years (2021 to 2025), Cumberland Pharmaceuticals's EPS (basic) has grown at a -5.7% compound annual growth rate (CAGR), from -$0.24 to -$0.19.
What does EPS (basic) mean?
Net income available to common shareholders divided by the weighted-average number of common shares outstanding during the period. Does not account for dilutive securities.